Business context and reporting period
The supplied filing is Diffusion Pharmaceuticals Inc.’s unaudited Form 10-Q for the quarter and six months ended June 30, 2019—not a filing for Cervomed Inc. The company is a clinical-stage biotechnology business developing trans sodium crocetinate (TSC) for conditions involving oxygen deprivation, including glioblastoma and acute stroke. It reported no product revenue.
Key financial metrics
| Metric | Three months ended June 30, 2019 | Six months ended June 30, 2019 | Comparable 2018 period |
|---|---|---|---|
| Research and development expense | $1.52 million | $3.22 million | $1.39 million and $3.22 million |
| General and administrative expense | $1.07 million | $2.27 million | $1.66 million and $3.16 million |
| Operating loss | $2.62 million | $5.54 million | $3.08 million and $6.43 million |
| Net loss | $2.50 million | $5.24 million | $2.77 million and $6.08 million |
| Net loss per share | $0.63 | $1.43 | $0.82 and $4.64 |
| Operating cash used | Not presented by quarter | $5.27 million | $5.83 million |
At June 30, cash and cash equivalents were $8.37 million, versus $7.99 million at December 31, 2018. Working capital was $8.4 million; total assets were $18.93 million and stockholders’ equity was $16.18 million. The company reported no credit facilities or committed sources of capital. No product-sales revenue or revenue-based margins were reported.
Six-month financing activities provided $5.65 million, primarily from the May stock-and-warrant offering; cash increased by $0.38 million over the period. The company had $1.04 million of current liabilities, including $0.11 million of current operating lease liability, and $0.18 million of noncurrent lease liability. The filing reports no outstanding conventional debt at period-end.
Changes versus the prior comparable period
Second-quarter net loss narrowed by approximately $0.27 million year over year; first-half net loss narrowed by approximately $0.84 million. First-half operating expenses decreased, primarily because general and administrative expense fell by $0.89 million, while R&D expense was essentially unchanged. Management attributed the R&D mix shift to increased spending on the Phase 2 stroke trial, offset by lower spending on the Phase 3 glioblastoma trial. First-half operating cash use improved by approximately $0.56 million, while financing proceeds were lower than in 2018.
In May 2019, the company issued 1,317,060 common shares and warrants for an aggregate $5.6 million in net proceeds. Common shares outstanding increased from 3,376,230 at year-end 2018 to 4,693,290 at June 30, 2019. The company adopted lease-accounting standard ASC 842, recognizing a $0.3 million right-of-use asset and corresponding lease liabilities; adoption did not affect reported operations or cash flows.
Outlook, risks and unusual items
- Management estimated cash would fund operations into the first quarter of 2020, but stated that substantial additional financing is required. The filing says the company’s recurring losses and dependence on raising capital raise substantial doubt about its ability to continue as a going concern.
- The Phase 2 PHAST-TSC acute-stroke trial was expected to begin enrollment in the third quarter of 2019, subject to funding; management anticipated initial data readout in the first half of 2021. The planned 160-patient study involves in-ambulance dosing.
- The Phase 3 INTACT trial in inoperable glioblastoma had completed its open-label safety run-in. Management expected data from that phase in the third quarter of 2019; randomized enrollment depended on a strategic partnership providing resources for the full trial.
- Management expected expenses to rise as clinical development proceeds. Failure to obtain financing could delay, scale back, or end programs, require collaborations or other strategic alternatives, or result in cessation of operations; equity financing could dilute shareholders.
- A former CEO’s arbitration matter was scheduled for November 2019. The company said it believed the claim lacked merit, but could not estimate the outcome or any possible loss; an adverse resolution could materially affect financial position.
- The company reported an income-tax benefit of $0.11 million for the quarter and $0.26 million for the six months, associated with deferred tax accounting under the 2017 Tax Act. No impairment was recorded for the RES-529 intangible asset in the six-month period.
Important facts for investors to verify
- Confirm the intended issuer: the filing supplied is for Diffusion Pharmaceuticals Inc., although the request metadata names Cervomed Inc.
- Check whether the stated cash runway and financing assumptions remain valid, and whether additional capital or a strategic partnership was obtained.
- Verify actual enrollment, timing, and subsequent results for the PHAST-TSC and INTACT clinical programs.
- Assess dilution and potential warrant overhang from the May 2019 offering and other outstanding warrants.
- Review subsequent developments in the former CEO arbitration and the company’s going-concern disclosures.